Meeting
2019 Genitourinary Cancers Symposium
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
Authors
Noah M. Hahn
Johns Hopkins University School of Medicine, Baltimore, MD
Noah M. Hahn , Sam S. Chang , Maxwell Meng , Neal D. Shore , Badrinath R. Konety , Gary D. Steinberg , Juergen E. Gschwend , Hiroyuki Nishiyama , Juan Palou Redorta , John Arthur Taylor III, Ayanbola Elegbe , Alexandre Lambert , Li Zhu , Yuko Ishii , Toshiki Maeda , Bradley Raybold , Gary Grossfeld , Bruce S. Fischer , Mark Rutstein , Alfred Witjes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT03519256
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS493)
DOI
10.1200/JCO.2019.37.7_suppl.TPS493
Abstract #
TPS493
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.
First Author: Noah M. Hahn
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2024 ASCO Genitourinary Cancers Symposium
Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
First Author: Zongren Wang
Poster
2022 ASCO Annual Meeting
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel